Evidence map›Paper›PMID 32215854›Full record

ArticlePharmacological reports : PR2020

Changes in PCSK9 and LDL cholesterol concentrations by everolimus treatment and their effects on polymorphisms in PCSK9 and mTORC1.

Shiori Sato, Yumiko Akamine, Hideaki Kagaya, Mitsuru Saito, Takamitsu Inoue, Kazuyuki Numakura, Tomonori Habuchi, Shigeru Satoh, Masatomo Miura

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmacological reports : PR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Cardiovascular effects of immunosuppression agents.Frontiers in cardiovascular medicine · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Shiori SatoDepartment of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita, 010-8543, Japan.
Yumiko AkamineDepartment of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita, 010-8543, Japan.
Hideaki KagayaDepartment of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita, 010-8543, Japan.
Mitsuru SaitoDepartment of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, Japan.
Takamitsu InoueDepartment of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, Japan.
Kazuyuki NumakuraDepartment of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, Japan.
Tomonori HabuchiDepartment of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita, Japan.
Shigeru SatohCenter for Kidney Disease and Transplantation, Akita University Hospital, 1-1-1 Hondo, Akita, Japan.
Masatomo MiuraDepartment of Pharmacy, Akita University Hospital, 1-1-1 Hondo, Akita, 010-8543, Japan. m-miura@hos.akita-u.ac.jp.
Akita University · JPAkita University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe purpose of this study was to evaluate the effects of concentrations of proprotein convertase subtilisin/kexin type 9 (PCSK9) and low-density lipoprotein (LDL) cholesterol by the mammalian target of rapamycin (mTOR) inhibitor everolimus and their effects on genetic polymorphisms in the PCSK9 and mTORC1 genes in 53 renal transplant recipients.

methodsPrior to and on day 15 after everolimus administration, the concentrations of everolimus in blood and PCSK9 and LDL cholesterol in plasma were evaluated. Additionally, mTORC1 (rs2536T>C and rs2295080T>G) and PCSK9 (rs505151G>A, rs562556G>A, and rs11593680C>T) polymorphisms were analyzed.

resultsMean PCSK9 plasma concentrations on day 15 after everolimus treatment were significantly higher than those before treatment (295 versus 214 ng/mL, respectively; p = 0.004). Significant correlations between the area under the blood concentration-time curves (AUC)

conclusionsAdministration of everolimus significantly elevated plasma PCSK9 concentrations, potentially causing everolimus-induced hyperlipidemia.

Indexed as

Cholesterol, LDLEverolimusFemaleHumansMaleMechanistic Target of Rapamycin Complex 1Polymorphism, GeneticProprotein Convertase 9Cholesterol, LDLEverolimusMechanistic Target of Rapamycin Complex 1PCSK9 protein, humanProprotein Convertase 9EverolimusLow-density lipoprotein cholesterolMammalian target of rapamycin complex 1PolymorphismProprotein convertase subtilisin/kexin type 9

Identifiers

PMID32215854
OpenAlexW3013964471

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.